Acquisition - January 8, 2016
Sobi gains commercial rights from Pharma Swiss
Swedish Orphan Biovitrum AB has gained commercial rights from the Swiss based company PharmaSwiss SA, to distribute Relistor®, Deflux® and Solesta® in a territory including Western Europe, Czech Republic, Slovakia, Hungary and also for Relistor in Russia. “I am delighted that we have expanded our successful partnership with PharmaSwiss and provide patients and physicians with […]
Acquisition - January 4, 2016
Sectra acquires Rx Eye
Sectra has acquired the Swedish company RxEye, which sells cloud-based IT services for efficient and secure remote viewing of medical images. The services are used, for example, by radiology, nuclear medicine and pathology departments, as well as by companies that sell teleradiology services. Through its RxEye Cloud service, RxEye has built up a network for […]
Acquisition - December 22, 2015
Karo Bio acquires Allevo
Karo Bio acquires Allevo rights from Cederroth for SEK 60 mln. The company acquires rights to weight control product range Allevo from Cederroth for some 60 million Swedish crowns ($7 million). According to reuters Allevo yearly revenues is 62 million crowns. In order to finance the acquisition Karo Bio will use a short-term credit corresponding to the […]
Acquisition - December 17, 2015
CareDx to acquire Allenex
CareDx announced an agreement to acquire approximately 78% of the outstanding shares of Allenex AB from its three principal shareholders, and plans to launch a tender offer for the remaining 22% of the shares of Allenex in the first quarter of 2016. The Allenex Board of Directors has unanimously recommended that Allenex shareholders accept the […]
Acquisition - December 17, 2015
Vironova acquires NOW Electronics
The acquisition of NOW is part of a long term plan of Vironova of building a strong technology platform to enable further development of electron microscopy based analysis tools for nanoparticle characterization. Vironova has together with NOW developed a camera specialized for electron microscopy use. “By a closer integration of the expertise of NOW and […]
Acquisition - December 17, 2015
AstraZeneca buys most of Acerta for $4 billion
AstraZeneca has entered into an agreement to invest in a majority equity stake in Acerta Pharma, a privately-owned biopharmaceutical company based in the Netherlands and US. The transaction provides AstraZeneca with an irreversible oral Bruton’s tyrosine kinase (BTK) inhibitor, acalabrutinib (ACP-196), currently in Phase III development for B-cell blood cancers and in Phase I/II clinical […]
